Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines More
Novel series of heterocyclic compounds which have been tested and screened for growth inhibitory activity (IC50) against the K562 human chronic myelogenous leukemia cell-line using the MTT assay and for their ability to inhibit the tubulin assembly. More
Opticin has been found to exhibit anti-angiogenic (blood vessel formation) effects on a range of cell lines from different cancers More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2009 - $15,200
Dec 2010 - 19 pages - $99
Nov 2010 - 26 pages - $125
Nov 2010 - 40 pages - $500
Jun 2011 - 77 pages - $1,000
Aug 2011 - 122 pages - $1,000
Jul 2011 - 110 pages - $500
Nov 2010 - 40 pages - $500
May 2011 - 5 pages - $500
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us